Fewer than 10% of individuals that would benefit from obesity jabs like Wegovy can access them, warns the WHO as it issues its initial advice on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to GLP-1 medication.
Based on forecasts, more than two billion could be living with obesity by 2030 unless action is taken.
"The new guidance recognises that excess weight is a chronic disease that can be managed with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to widespread access to the jabs that can help people shift substantial body mass, explains the body.
GLP-1 Therapy Supply Crisis
Despite the present most favorable case, the supply of these medications could only cover approximately 100 million people – less than 10% of the global need, according to the WHO.
The recommendation urges governments and firms to widen access, by strategies including patent sharing.
The intellectual property rights on a key compound – the core ingredient of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Work
The injections replicate a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so people reduce food intake.
Individuals usually see weight reduction within a few weeks of commencing the regular doses.
Evidence suggests users may see weight return a year later of halting the medication, as their typical hunger come back.
Being carrying excess weight increases your risk for developing medical conditions, including diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
